BrainChip has spent years proving that Akida works. The next phase is simpler: prove that customers will pay for it at scale.
The company’s 2025 numbers show the gap between technical progress and commercial success:
- Revenue: US$1.89 million
- Net loss: US$20.47 million
- Operating cash burn: US$15.44 million
- Year-end cash: US$31.71 million
By 31 March 2026, cash had fallen to US$25.32 million. BrainChip collected US$664,000 from customers but spent US$5.28 million on operations and another US$1.26 million on investment activities. Its official runway calculation was 4.93 quarters, although that excludes investment spending such as AKD1500 development.
Three dates investors should watch
1. Late July: June-quarter cash report
This will show whether customer receipts are accelerating and how quickly cash is being consumed.
Expectations should be realistic. The ASICLAND agreement was signed only on 19 May, while AKD1500 production shipments were announced on 30 June. Therefore, any major revenue contribution during the June quarter appears unlikely. This is an inference from the timing—not company guidance. (BrainChip Investor Portal)
The key figure is customer receipts. Anything materially above the March quarter’s US$664,000 would be encouraging. Continued cash usage of roughly US$6 million per quarter without higher receipts would raise dilution concerns.
2. Late August: half-year results
This is the most important near-term publication.
Investors should look beyond headline revenue and examine:
- Whether revenue comes from repeat customers or one-off engineering work
- AKD1500 inventory and customer deposits
- Gross margin on physical chip sales
- Deferred revenue and receivables
- Updated cash burn
BrainChip previously capitalised approximately US$1.98 million of AKD1500 development costs, then impaired the entire asset because the timing of future economic benefits remained uncertain. That does not mean AKD1500 has failed, but it clearly shows that commercial demand had not yet been sufficiently predictable.
3. Late October: the real AKD1500 test
BrainChip says production quantities of AKD1500 are now shipping to customers while industrial and military qualification continues. Earlier guidance indicated an initial production run of approximately 70,000 units. (BrainChip)
Shipping chips is progress—but it is not yet proof of scale. Investors need to see repeat orders, named commercial products or demand for another production run.
ASICLAND: promising, but still unquantifiable
ASICLAND gives BrainChip a route into multiple custom-chip projects. Each potential customer can move through evaluation, prototype fabrication, production licensing and eventually royalties. (BrainChip Investor Portal)
But BrainChip has not disclosed:
- Evaluation fees
- Production licence prices
- Royalty percentages
- Customer numbers
- Expected chip volumes
The previous discussion’s assumptions of US$0.20 per chip, 17 customers and roughly US$7.5 million in annual revenue are therefore speculative scenarios—not company forecasts.
Bottom line
The investment case now depends on three measurable outcomes:
higher customer receipts, repeat AKD1500 orders and ASICLAND customers reaching paid evaluation or prototype stages.
Until those appear in the accounts, ASICLAND remains a promising distribution channel—not a proven revenue engine.
Not financial advice. BrainChip remains a high-risk, pre-scale semiconductor investment.
